Tempus AI (TEM) said Thursday that it has expanded its partnership with Takeda Pharmaceutical (TAK) to support Takeda's oncology research and development using real-world multimodal datasets and biological model systems.
Financial terms of the new agreement were not provided.
Tempus AI said Takeda will use Tempus AI' real-world data and AI tools for its cancer therapeutic pipeline.
The companies have also initiated a multi-phase project using patient-derived tumor organoids linked to Tempus' genetic sequencing, aiming to improve drug candidate prioritization and effectiveness predictions, Tempus said.
Shares of Tempus were up 1.7% in recent premarket activity, while Takeda was marginally down by 0.2%.
Price: 50.16, Change: +1.01, Percent Change: +2.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.